Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

Iridex trims full-year sales outlook as European and Asian laser demand softens

The US ophthalmic laser maker posted a quarterly revenue fall of $2.3M, remains loss-making despite a better gross margin, and is reassessing its product range and factory footprint.

17 Nov 2026 · Iridex Corp IRIX · Company news

Iridex, which sells laser systems and consumable probes for glaucoma and retinal disease, now expects 2026 revenue of $46M to $48M, after a third quarter in which sales fell well short of the prior-year level. Revenue for the period ended 3 October was $10.2M, compared with $12.5M a year earlier, a drop of nearly a fifth. The company reported the results on 17 November.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Iridex Corp ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →